Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib + FOLFIRI in metastatic colorectal cancer
NCT03556956Phase 3Completed
- Sponsor
- AB Science
- Start
- Jul 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal cancer (mCRC) comparing Masitinib plus FOLFIRI with Best Supportive Care (2 arms). Primary endpoint: Overall Survival at 60 months. Started Jul 2015; status: completed.
02
Drugs
masitinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03556956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556956.